



Pioneering science delivers vital medicines™

Amgen 2012 Environmental Sustainability Highlights



Leadership Message



Robert A. Bradway

As we deliver more therapies to more patients suffering from serious illnesses around the world, it remains critical that we do so in a way that is consistent with our mission and our values.

Over the past 33 years, we have grown to be a leader in biotechnology and we have reached more than 25 million patients. During the course of that journey, innovation has played a pivotal role. As a company, we have innovated by discovering and developing medicines that have dramatically improved people's lives. In addition, we have played a pioneering role in biologics manufacturing through scores of innovations that have enabled us to deliver vital medicines to large patient populations.

We expect to continue transforming our manufacturing process in the years ahead. An important part of that next wave of manufacturing innovation will involve reducing waste while improving efficiencies and incorporating greater flexibility into the process. As we embark on this exciting new chapter in our company's history, our commitment to operating in a way that reduces environmental impacts remains steadfast.

We achieved the targets that we set in 2008 as part of our first environmental sustainability plan. From 2008 through 2012, we realized more than \$24 million in cost savings by implementing strategic sustainability initiatives. And we made those conservation gains even as we grew operations worldwide.

As part of our sustainability initiatives, our staff eliminated waste and created efficiencies through our Green Chemistry and Green Biology programs. We remodeled facilities for expansion with green features, and in 2012, we achieved

a LEED (Leadership in Energy and Environmental Design) Gold designation for an Amgen building. Our initial integration of environmental sustainability principles into our products and processes will form the foundation of our second environmental sustainability plan, beginning in 2013, which will take us through 2020.

I view the state-of-the-art manufacturing facility we are planning in Singapore as the best example to date of how our growth intersects with our environmental sustainability goals. This innovative, new facility is expected to conserve resources and save costs, thereby contributing to the consistent supply of safe and effective medicines to patients who need them.

Staff members, who are passionate about our mission, represent our most important resource. Creating a supportive work environment that keeps them safe and well is a primary part of our culture. We have a comprehensive and effective set of wellness programs for staff as well as one of the best safety records in our industry.

Thank you for following our progress as we continue to reduce environmental impacts, improve efficiencies, and decrease costs. These sustainability achievements exemplify how science and innovation applied across Amgen support our aspiration to dramatically improve patients' lives.

A handwritten signature in black ink that reads "Robert A. Bradway". The signature is written in a cursive, flowing style.

Robert A. Bradway
Chairman and Chief Executive Officer

This brochure, a supplement to Amgen's 2012 Environmental Sustainability Report found at environment.amgen.com, highlights how the Company has successfully implemented an environmental sustainability plan in a data-driven and strategic way. We achieved the six 2012 targets we set for environmental sustainability improvement, and we now begin work in 2013 on a new plan and targets for 2020.

Our Targets




In 2008, we set six environmental targets: energy, carbon dioxide, water, waste recycling, waste reduction, and the fuel efficiency of our US sales fleet—all of which we've achieved. We saved more than \$24 million in costs from 2008 to 2012 as a result of striving toward those targets and achieving efficiency gains. For 2020, we have set new targets in the areas of facility carbon emissions, fleet carbon emissions, and disposed waste reduction, emphasizing a continued focus on reducing greenhouse gases as well as the amount of waste we dispose.

2012 Target

Final Results

- Energy** Reduce 500,000 gigajoules (GJ)
12% of 2007 baseline
- Carbon dioxide** Reduce 75,000 metric tons (MT)
18% of 2007 baseline
- Water** Reduce 235,000 cubic meters (m³)
7% of 2007 baseline
- Recycling** Divert more than 40%
2007 rate was 38%
- Waste** Reduce 700 metric tons (MT)
7% of 2007 baseline
- Fuel efficiency** Improve by 4 miles per gallon (MPG)
23% of 2007 baseline



From developing molecules to installing building technologies, we're integrating environmental sustainability into many core areas of Amgen's business. We share our environmental ethic through volunteering in our communities worldwide.

Sustainability in Action



Left: We renovated a building in Thousand Oaks, California, that combines green building techniques with enhanced collaboration approaches.

Right: Green chemistry and green biology practices improve efficiency.

Building Renovation Earns LEED Gold

In 2012, Amgen earned LEED (Leadership in Energy and Environmental Design) Gold for the renovation of an administrative building at our Thousand Oaks, California, campus. The building is designed to provide energy and water conservation benefits exceeding current industry baseline standards. Additionally, the building incorporates abundant natural light, state-of-the-art technology, and flexible work areas and meeting spaces to facilitate the way people work today. This renovation, a pilot project, has set an example for all of Amgen's office space construction for 2012 and beyond.

Innovations Reduce Carbon Footprint of Manufacturing

Facilities to load drug product into vials and syringes traditionally consume large amounts of energy, but at our new manufacturing building in Puerto Rico, updated technologies have reduced energy use by 25 percent and fuel requirements by 40 percent over traditional methods. That facility design eliminated 8,730 metric tons of carbon dioxide in 2012, thereby helping us achieve our carbon target in 2012. Energy-efficient lighting as well as equipment that uses less water adds to the conservation benefits of that new construction.

Better Processes through Greener Biology and Chemistry

As part of a green biology emphasis, Amgen is beginning to switch to advanced chromatography methods that lead to energy and water conservation, waste reduction, and reduced solvent use. Amgen is including sustainability

considerations in the annual review of our monoclonal antibody platform and is participating in industry-wide efforts to measure the environmental footprint of large-molecule manufacturing.

Our small-molecule and medicinal chemistry teams are demonstrating the direct relationship between process cost reduction and green chemistry practices. These conservation results are good for the environment, and they deliver enhanced process efficiency and added value for our stakeholders. We have advanced our use of solvent-selection tools, integrating them into our Small Molecule Process & Product Development electronic notebook. Amgen is very active in several prominent green chemistry industry organizations.

Greener Packaging

We're making steady progress toward more-environmentally-friendly approaches in the delivery, packaging, and end of use of our medicines. Our Sharps Mail-Back program for patients using Enbrel® (etanercept) grew in the first full year of the program, keeping approximately 17 metric tons of sharps medical waste from landfills per quarter. In 2012, we approved the use of paperboard from certified-sustainable forests in our clinical and commercial secondary packaging. Using our Green Packaging Assessment Process, we are evaluating the sustainable qualities of new secondary packaging materials. Our program to expand the printing of recycling logos on secondary packaging also expanded in 2012.

Amgen makes an impact in the communities in which we operate through direct volunteer work by staff members and through financial support from the Amgen Foundation. We are a good neighbor in the communities where we work and live.



Above: Amgen staff volunteer in their communities. They removed nearly four metric tons of trash during the 2012 International Coastal Cleanup.

Volunteering for the Environment

Collecting, hauling, and planting as they go, Amgen staff around the world are protecting and restoring the environment in their communities. From British Columbia to Puerto Rico, hundreds of Amgen staff members cleared nearly 4 metric tons of debris from beaches and waterways as part of the September 2012 International Coastal Cleanup. In 2012, Amgen was awarded the Boulder County, Colorado, Parks and Open Space Partnership Award for conservation activities at Pella Crossing, a wetland conservation park and other open-space lands. Since 2009, Amgen has contributed close to 600 hours of volunteer service each year in helping care for these lands.

Community plant restoration events grow year by year at Amgen. Staff members from Thousand Oaks, California, have made numerous treks to Anacapa Island in California's Channel Islands to remove nonnative, invasive ice plant—vegetation that has been overwhelming native plant species and inhibiting the food sources of native wildlife since it was introduced in the 1940s. Staff also replant cleared areas with native plants grown from island-collected seed. In Australia, staff members planted 300 native seedlings in an area of bush close to Amgen's Sydney office. The group helped transform an area previously overrun with weeds into an area that will encourage native birds and insects.

The Amgen Foundation Supports the Environment

The Amgen Foundation placed special emphasis on water through the National Fish and Wildlife Foundation's Five Star Restoration Program beginning in 2012. Through this program, the Amgen Foundation will provide financial assistance on a competitive basis for community-based wetland, riparian, and coastal habitat restoration projects. Additionally in 2012, the Amgen Foundation continued its long-standing support of NatureBridge: Science in the Outdoors, enabling students to visit the program's residential program for several days at a time. The Foundation also continued support of the National Wildlife Federation's Eco-Schools USA program in Ventura County, California.

Two of the Foundation's 10 honorees for Excellence in Volunteering are involved in environmental conservation. One honoree, a water-sports enthusiast, volunteers with the Scuba Dogs Society in Puerto Rico to remove tons of waste from coastal areas of the island every year. Another was singled out for her volunteer work at the Seattle Aquarium, which began when she was a teen naturalist in 1994.

See the Amgen Foundation 2012 Charitable Contributions Report for more information on the wide variety of nonprofits the Foundation supports in communities across the United States, Puerto Rico, and Europe.

Performance




Conserving Resources

Energy conservation has a direct impact on the amount of carbon dioxide (CO₂) we emit through operations. We started our sustainability approach by tackling large projects that provided big returns for both energy savings and carbon reduction across our network of facilities around the world. Most recently, we've looked at new technologies for product manufacturing that provide energy and carbon reduction benefits. Energy conservation and carbon reduction projects have saved our Company close to \$17 million annually and reduced carbon emissions by 83,000 metric tons since 2008.

Our improvement target for the fuel efficiency of our US sales fleet, which we met in 2012, has driven our approach to fleet management over the years. We've steadily expanded fuel-efficient vehicle choices available for mobile staff, rotating less-fuel-efficient vehicles out of the fleet for more-efficient options that achieve 23 miles per gallon or higher.

Carbon Dioxide


2007–2012 Emissions and Carbon Dioxide Emissions Avoided* through Conservation Efforts (1,000 MT)



*Value represents year-over-year, cumulative avoidance.

Energy


2007–2012 Energy Use and Energy Use Avoided* through Conservation Efforts (1,000 GJ)



*Value represents year-over-year, cumulative avoidance.

Fuel Efficiency

2007–2012 US Fleet Fuel Use and Fuel Use Avoided¹ through Conservation (per 1,000 Gal)




¹Chart represents annual avoidance.




Waste

The Waste Hierarchy as a Model for Our Waste-Reduction Goals




Routine Waste Chart 2007–2012 by Waste Hierarchy (MT)



Water

2007–2011 Water Intake and Intake Avoided* through Conservation Efforts (1,000 m³)



*Value represents year-over-year, cumulative avoidance.

Reducing Waste, Saving Water

We diverted more than 26,500 metric tons of waste and improved our overall recycling rate from 38 percent to 59 percent from 2007 through 2012 through staff commitment to recycling and waste reduction programs. We identified a multitude of ways to recycle, including composting landscape, food, and disposable food-service waste, and reusing equipment and office supplies on-site. With this success as a foundation, we shifted to the practice of reducing the waste at its source.

Amgen continuously strives to conserve water, which is a vital component of our medicines. Water conservation solutions we've implemented include a wastewater treatment plant in Puerto Rico that has enabled an average of 70 percent of the treated wastewater generated at the facility to be recycled on-site each year, and low-water landscaping and smart-irrigation controls at a variety of facilities.

Looking Ahead



Amgen's 2020 Plan

In 2013, we begin executing against a new sustainability plan that will take us through 2020. This plan now covers Amgen's entire value chain, allowing us to gain a better understanding of our supplier impact, as well as to increase the integration of sustainability into our products and processes. Building on our culture of environmental sustainability, we will continue driving sustainable practices in the areas of Research and Development, Manufacturing and Operations, Transportation and Distribution, Commercial Operations, Sourcing, and Product Stewardship.

Whereas our 2012 plan focused sharply on implementing conservation projects to increase efficiencies in our existing facilities, our 2020 plan will achieve results from designing in sustainability during process and product development. By making sustainability part of the design process, we will achieve further efficiencies in our business while continuing to reduce our impact on the environment.

As part of our plan, we have committed to achieving new targets:

- Reduce facility carbon emissions by 10 percent
- Reduce fleet carbon emissions by 20 percent
- Reduce disposed waste by 35 percent

We will work to better understand the local water issues and conditions at our facilities, after which we will set a water reduction target.

We realize that staff innovation drives our progress in environmental sustainability. Our focus is on building an even stronger culture where staff innovation is encouraged and recognition given for contributions toward reducing Amgen's environmental impact. Staff can have a positive impact in many areas including Green Chemistry, Green Biology, and Green Packaging.

Staff will be particularly engaged in digging more deeply to find further opportunities across our entire value chain to innovate our processes to increase efficiency and reduce wasted resources. By broadening our plan to cover our value chain, we will be better able to understand the impact of our suppliers and work to improve our partnership and reduce risk. By furthering our reach across our value chain we will begin to have a greater impact not only on our own products and processes, but those of our suppliers as well.

Our 2020 sustainability plan is designed to strengthen our business and contribute to our mission to serve patients by creating efficiencies, saving resources, and reducing risk.

Amgen reports in alignment with the Global Reporting Initiative (GRI) G3.1 guidelines. The GRI guidelines offer a useful framework to help companies standardize their sustainability reporting. We are reporting on our 2012 performance at an application level C+, which has been GRI checked. See environment.amgen.com (GRI Check).

The scope of the environmental data in our report includes 15 manufacturing, research and development, and distribution facilities in North America and Europe. These facilities represent approximately 95 percent of our operations, based on the square footage of our facilities. The remaining square footage primarily includes administrative offices.

Our 2012 environmental data for this report has undergone limited assurance by Bureau Veritas.

In 2012, Amgen acquired four companies: Micromet, KAI Pharmaceuticals, deCODE genetics, and Mustafa Nevzat Pharmaceuticals. No data will be included for these facilities in this report, as we are still working through the integration process.

The index summarizes Amgen's disclosures in relation to the GRI G3.1 indicators.

Strategy and Analysis

Number	Disclosure	Reported	Response
1.1	Statement from CEO	●	environment.amgen.com (Leadership Message)

Organizational Profile

Number	Disclosure	Reported	Response
2.1	Name of organization	●	Amgen
2.2	Primary brands, products, and/or services	●	www.amgen.com (Product websites)
2.3	Operational structure	●	www.amgen.com (Amgen Fact Sheet)
2.4	Location of headquarters	●	Thousand Oaks, CA
2.5	Countries of operation	●	www.amgen.com (Amgen Fact Sheet)
2.6	Nature of ownership	●	www.amgen.com (Amgen Fact Sheet)
2.7	Markets served	●	www.amgen.com (Amgen Fact Sheet)
2.8	Scale of the reporting organization	●	www.amgen.com (Amgen Fact Sheet)
2.9	Significant changes during the reporting period	●	Amgen acquired four companies in 2012: Micromet, KAI Pharmaceuticals, deCODE genetics, and Mustafa Nevzat Pharmaceuticals. Robert Bradway became the Company's new CEO effective May 23, 2012, and the Chairman of the Board effective January 1, 2013.
2.10	Awards	●	environment.amgen.com (Environmental Awards and Recognition)

Report Parameters

Number	Disclosure	Reported	Response
3.1	Reporting period	●	January 1, 2012, to December 31, 2012
3.2	Date of most recent report	●	May 2012
3.3	Reporting cycle	●	Annual
3.4	Contact point	●	esfeedback@amgen.com
3.5	Process for defining report content	●	environment.amgen.com (Amgen's Environmental Sustainability Plan) environment.amgen.com (Stakeholder Engagement)
3.6	Boundary of the report	●	Amgen facilities within the scope of this report are as follows: United States: Thousand Oaks, California; Cambridge, Massachusetts; Woburn, Massachusetts; Greenwich, Rhode Island; Louisville, Kentucky; South San Francisco, California; Boulder and Longmont, Colorado; Juncos, Puerto Rico; Seattle and Bothell, Washington; Field Sales US Fleet Canada: Burnaby, British Columbia Europe: Breda, Netherlands; Uxbridge, Abingdon, and Cambridge, United Kingdom; Dun Laoghaire, Ireland

Report Parameters (continued)

Number	Disclosure	Reported	Response
3.7	Limitations on the scope and boundary of the report	●	Items that are out of scope for this report include global sales and administrative offices with minimal environmental impact; outsourced activities, such as contract manufacturers; companies acquired in 2012, including Micromet, KAI Pharmaceuticals, deCODE genetics, and Mustafa Nevzat Pharmaceuticals; and Amgen's facility in São Paulo, Brazil, acquired in 2011.
3.8	Basis for reporting	●	The in-scope facilities listed in indicator 3.6 represent our 15 manufacturing, research and development, and distribution facilities in North America, Europe, and Puerto Rico. These facilities represent 95 percent of our operations, based on the square footage of our facilities. The remaining square footage primarily includes administrative offices. We do not include environmental data from outsourced activities in this report.
3.9	Data measurement techniques and bases of calculations and assumptions	●	environment.amgen.com (Summary of Data Notes)
3.10	Explanation of the effect of any re-statements	●	No restatements
3.11	Significant changes from previous reporting periods	●	Amgen acquired four companies in 2012 including Micromet, KAI Pharmaceuticals, deCODE genetics, and Mustafa Nevzat Pharmaceuticals. For the 2012 report, environmental data from these facilities will not be included.
3.12	GRI content index table	●	environment.amgen.com (GRI Index)

Governance, Commitments, and Engagement

Number	Disclosure	Reported	Response
4.1	Governance structure including committees	●	environment.amgen.com (Governance) www.amgen.com (Corporate Governance)
4.2	Indicate whether the chair of the highest governance body is also an executive officer	●	Robert Bradway is both CEO and Chairman of the Board. For more information on Amgen's Board, see amgen.com (Corporate Governance)
4.3	Unitary board structure	●	www.amgen.com (Corporate Governance)
4.4	Mechanisms for shareholders and employees to provide recommendations/direction to highest governance board	●	www.amgen.com (Corporate Governance)
4.14	List of stakeholder groups engaged by the organization	●	environment.amgen.com (Stakeholder Engagement)
4.15	Basis for identification and selection of stakeholders with whom to engage	●	environment.amgen.com (Stakeholder Engagement)

Economic Performance Indicators

Number	Disclosure	Reported	Response
EC1	Economic Performance: Direct economic value generated and distributed	◐	environment.amgen.com (Summary of Data and Data Notes) www.amgen.com (2012 Annual Report and Financial Summary)
EC2	Economic Performance: Financial implications and other risks and opportunities due to climate change	●	We're actively working to conserve energy and reduce greenhouse gas emissions that result from our operations. We have also considered potential risks to our business associated with climate change such as extreme weather events and increasing regulation. Financial impact is considered as part of our risk management processes. Having plans in place to mitigate these risks increases the overall sustainability of the business.
EC9	Indirect Economic Impacts: Understanding and describing significant indirect economic impacts, including the extent of impacts	◐	www.amgen.com (AmgenAssist)

Environmental Performance Indicators

Number	Disclosure	Reported	Response
EN3	Energy: Direct energy consumption by primary energy source	●	environment.amgen.com (Energy Sources) environment.amgen.com (Summary of Data)
EN4	Energy: Indirect energy consumption by primary source	●	environment.amgen.com (Energy Sources) environment.amgen.com (Summary of Data)
EN5	Energy: Energy saved due to conservation and efficiency improvements	●	environment.amgen.com (Energy Approach) environment.amgen.com (Summary of Data) environment.amgen.com (Targets)
EN7	Energy: Initiatives to reduce indirect energy consumption and reductions achieved	●	environment.amgen.com (Energy and Carbon Approach) environment.amgen.com (Targets)
EN8	Water: Total water withdrawal by source	●	environment.amgen.com (Water Approach) environment.amgen.com (Summary of Data)
EN10	Water: Percentage and total volume of water recycled and reused	●	environment.amgen.com (Water Approach) environment.amgen.com (Summary of Data)
EN16	Emissions, Effluents and Waste: Total direct and indirect greenhouse gas emissions by weight	●	environment.amgen.com (Carbon Performance) environment.amgen.com (Summary of Data)
EN17	Other relevant indirect greenhouse gas emissions by weight	◐	environment.amgen.com (Carbon Approach)
EN18	Emissions, Effluents and Waste: Initiatives to reduce greenhouse gas emissions and reductions achieved	●	environment.amgen.com (Energy and Carbon Performance) environment.amgen.com (Summary of Data) environment.amgen.com (Targets)
EN22	Emissions, Effluents and Waste: Total weight of waste by type and disposal method	●	environment.amgen.com (Summary of Data)
EN23	Emissions, Effluents and Waste: Total number and volume of significant spills	●	There were no significant spills in 2012.
EN27	Products and Services: Percentage of products sold and their packaging materials that are reclaimed by category	◐	environment.amgen.com (Stakeholder Engagement)
EN28	Compliance: Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with environmental laws and regulations	●	In 2012 Amgen received two environmental notices of violation as a result of agency inspections. There were no fines associated with these notices of violation.
EN29	Significant environmental impacts of transporting products and other goods and materials used for the organization's operations, and transporting members of the workforce	◐	environment.amgen.com (Carbon Approach) environment.amgen.com (Summary of Data)

Labor Practices and Decent Work Performance Indicators

Number	Disclosure	Reported	Response
LA7	Occupational Health and Safety: Health and safety rates	◐	environment.amgen.com (Safe Workplace)
LA8	Occupational Health and Safety: Programs in place to assist workforce, families and communities regarding serious diseases	●	environment.amgen.com (Staff Wellness)

Society Performance Indicators

Number	Disclosure	Reported	Response
SO6	Total value of financial and in-kind contributions to political parties, politicians, and related institutions	●	www.amgen.com (Corporate Governance) environment.amgen.com (Summary of Data)

Product Responsibility Performance Indicators

Number	Disclosure	Reported	Response
PR1	Customer Health and Safety: Life cycle stages in which health and safety impacts of products are assessed for improvement, and percentage of products subject to such procedures	◐	www.amgen.com (Medicine Safety)

Energy (a)

Type	Unit	2007	2008	2009	2010	2011	2012
Total Combustion On-site (Direct) (d)	1,000 GJ	2,151	1,914	1,941	1,905	1,897	1,790
Natural Gas	1,000 GJ	1,848	1,632	1,588	1,522	1,462	1,390
Diesel	1,000 GJ	303	282	350	372	425	390
Propane	1,000 GJ	-	0.7	3	11	10	10
Total Purchased Energy (Indirect) (e)	1,000 GJ	2,190	2,104	2,065	2,011	2,006	2,059
Fossil Fuel	1,000 GJ	1,541	1,483	1,479	1,452	1,497	1,545
Hydro	1,000 GJ	287	281	265	252	196	191
Nuclear	1,000 GJ	240	224	210	200	194	195
Nonspecified Renewables	1,000 GJ	106	101	97	94	107	114
Nonspecified	1,000 GJ	16	15	14	14	13	13
Total Energy	1,000 GJ	4,341	4,019	4,006	3,916	3,903	3,849
Total Energy Normalized to Net Sales	1,000 GJ/\$B net sales	303	274	279	267	255	231
Confirmed Results of Energy Reduction Projects (b,c)	1,000 GJ	-	245	407	542	718	919

Carbon (a)

Type	Unit	2007	2008	2009	2010	2011	2012
Total Carbon Combustion On-site (Scope 1) (f)	1,000 MT CO ₂ Eq	126	113	115	114	104	98
Natural Gas	1,000 MT CO ₂ Eq	104	92	89	86	74	70
Diesel	1,000 MT CO ₂ Eq	22	21	26	27	30	27
Propane	1,000 MT CO ₂ Eq	-	0.04	0.16	0.68	0.60	0.63
Total Carbon Purchased Energy (Scope 2) (g)	1,000 MT CO ₂ Eq	290	278	296	294	277	287
Electricity	1,000 MT CO ₂ Eq	284	272	291	289	273	283
Steam	1,000 MT CO ₂ Eq	6	6	5	5	4	4
Total Carbon From Energy	1,000 MT CO ₂ Eq	416	391	412	407	381	385
Total Carbon Normalized to Net Sales	1,000 MT CO ₂ Eq/ \$B net sales	29.1	26.6	28.7	27.8	24.9	23.1
Total Carbon Normalized to Total Energy	MTCO ₂ Eq/GJ	0.095	0.097	0.102	0.104	0.098	0.100
Confirmed Results of CO ₂ Reduction Projects (b,c)	1,000 MT CO ₂	0	19	36	49	63	83

Other Carbon (h)

Type	Unit	2007	2008	2009	2010	2011	2012
Carbon US Sales Fleet (Scope 1)	1,000 MT CO ₂ Eq	13	13	12	16	16	15
Carbon US Sales Fleet Emissions Avoided (Scope 1)	1,000 MT CO ₂ Eq	0	0.1	1	3	3	4
Carbon Executive Air Fleet (Scope 1)	1,000 MT CO ₂ Eq	5	5	5	7	7	6
Carbon Business Travel - Commercial (Scope 3) (i,j)	1,000 MT CO ₂ Eq	-	-	31	36	50	65
Carbon from Amgen Materials Transportation (Scope 3) (i,j)	1,000 MT CO ₂ Eq	-	-	-	-	-	25

Water (a)

Type	Unit	2007	2008	2009	2010	2011	2012
Total Water Withdrawal (k,c)	1,000 CM	3,286	2,738	2,537	2,574	2,577	2,720
Municipal	1,000 CM	3,249	2,724	2,526	2,561	2,560	2,707
Other - (Reservoir) Trucked In	1,000 CM	8	8	6	-	-	-
Ground	1,000 CM	29	7	5	14	17	13
Total Water Withdrawal Normalized to Net Sales	1,000 CM/\$B net sales	230	186	177	176	169	163
Water Fate	1,000 CM	-	-	2,532	2,576	2,584	2,720
Recycled	1,000 CM	-	-	376	453	533	535
Consumed Into Products	1,000 CM	-	-	20	20	20	21
Lost to Evaporation	1,000 CM	-	-	649	736	633	713
Discharged to Treatment	1,000 CM	-	-	1,553	1,554	1,663	1,662
Discharged Directly to Environment	1,000 CM	-	-	310	267	267	324
Percentage of Water Recycled per Total Water Withdrawal	%	-	-	15	18	21	20
Confirmed Results of Water Reduction Projects (b)	1,000 CM	-	550	601	663	673	690

Waste (a, c)

Type	Unit	2007	2008	2009	2010	2011	2012
Recycling Rate (l)	%	38	49	57	58	59	59
Total Routine Waste	MT	10,146	8,835	8,710	9,127	9,645	9,018
Hazardous Waste	MT	1,343	1,065	1,003	1,154	1,116	1,180
Recycled	MT	251	266	225	209	235	245
Incinerated for Energy Recovery	MT	375	235	219	254	284	347
Incinerated Not for Energy Recovery	MT	523	472	446	524	424	422
Landfilled	MT	118	81	108	161	153	126
Treated (m)	MT	76	11	6	6	20	40
Nonhazardous Waste	MT	8,803	7,770	7,706	7,972	8,529	7,838
Composted	MT	260	317	408	524	485	583
Reused	MT	32	87	87	57	60	44
Recycled	MT	2,999	3,368	3,812	3,967	4,418	3,890
Incinerated for Energy Recovery	MT	432	451	341	426	397	576
Incinerated Not for Energy Recovery	MT	194	190	128	131	176	79
Landfilled	MT	4,885	3,358	2,930	2,867	2,985	2,662
Treated (m)	MT	-	-	-	-	8	3.8
Total Routine Waste Normalized to Net Sales	MT/\$B net sales	709	602	607	623	631	542
Total Nonroutine Waste (n)	MT	31,415	54,796	79,992	23,645	12,458	16,902
Confirmed Results of Routine Waste Reduction Projects (b)	MT	-	249	358	442	875	1,094

Fleet

Type	Unit	2007	2008	2009	2010	2011	2012
US Sales Fleet Fuel Efficiency (o)	MPG-US	18.7	18.9	21.2	22.2	22.6	23.3
US Sales Fleet Fuel Use Avoided	1,000 GL	-	14	169	345	363	427
US Sales Fleet Fuel Use	1,000 GL	1,498	1,443	1,297	1,849	1,784	1,739

Business Profile

Type	Unit	2007	2008	2009	2010	2011	2012
Net Sales	\$B	14.311	14.687	14.351	14.660	15.295	16.639
"Adjusted" Net Income (q)	\$B	4.804	4.885	5.014	5.024	4.858	5.119
"Adjusted" R&D Investment (q)	\$B	3.064	2.910	2.739	2.773	3.116	3.296
Corporate Political Contributions (US) (p)	\$Mil	0.584	0.777	0.424	1.144	0.704	0.532
Staff	# FTE	17,500	16,900	17,200	17,400	17,800	17,900

Health and Safety

Type	Unit	2007	2008	2009	2010	2011	2012
Absenteeism (r)	Percent days away	2.4	2.1	2.1	2.0	2.1	1.9
Injury and Illness Rate (Beyond First Aid) (s,c)	Number of injuries and illnesses per 100 staff members	0.81	0.76	0.55	0.57	0.68	0.54
Lost Day Case Rate (t)	Injuries with days away from work per 100 staff members	0.25	0.28	0.19	0.17	0.18	0.16
Severity Rate (u,c)	Number of days away from work per 100 staff members	8.20	10.05	7.82	5.90	5.46	5.89
Fatalities	# Fatalities	0	0	0	0	0	0
Contractor Injury and Illness Rate (Beyond First Aid) (v)	Incidents per 100 contractors	0.53	0.65	1.29	1.27	1.27	1.63
Contractor Lost Day Case Rate (v)	Incidents per 100 contractors	0.07	0.07	0.27	0.61	0.61	0.75
Contractor Fatalities	# Fatalities	0	0	0	0	0	0

Compliance (a)

Type	Unit	2007	2008	2009	2010	2011	2012
Environmental Notices of Violation (NOVs) (w)	# NOV	8	0	2	3	2	2

General

- (a) Amgen has included data from 15 facilities covering energy and carbon, water, and waste. The facilities represent approximately 95 percent of Amgen's worldwide facility space based on total square feet. Included facilities are in Thousand Oaks, California, US; Greenwich, Rhode Island, US; Boulder and Longmont, Colorado, US; Seattle and Bothell, Washington, US; Juncos, Puerto Rico, US; Louisville, Kentucky, US; South San Francisco, California, US; Cambridge and Woburn, Massachusetts, US; Burnaby, Canada; Breda, Netherlands; Dun Laoghaire, Ireland; and Uxbridge, Abingdon, and Cambridge, United Kingdom. This includes leased buildings where we have operational control over building infrastructure, including utilities. In 2011, Amgen divested of its Fremont, California, facility and acquired facilities in Dun Laoghaire, Woburn, and São Paulo. In 2012, Amgen acquired four companies: Micromet, KAI Pharmaceuticals, deCODE genetics, and Mustafa Nevzat Pharmaceuticals. In our 2012 report, data beginning in May 2011 through the end of 2012 will be included from our Dun Laoghaire facility, which we purchased in May 2011. Data will be included from our Woburn and Abingdon facilities beginning in March 2011 through the end of 2012. No data will be included for our São Paulo facility or for Micromet, KAI Pharmaceuticals, deCODE genetics, or Mustafa Nevzat Pharmaceuticals in this report, as we are still working through the integration process for these facilities.
- (b) Measurement and verification of conservation and reduction projects for energy and carbon dioxide, water, and waste are based on adaptation of the International Performance Measurement and Verification Protocol (IPMVP), Concepts and Options for Determining Energy and Water Savings Volume 1, EVO 10000-1.2007, April 2007. Project measurements are conducted using reasonable means, including direct measurements and scientific estimations as appropriate.
- (c) Small changes to 2007–11 data have occurred due to refinements in calculations. All changes have been confirmed through a documented change control process.

Energy

- (d) Direct energy use results from the operation of equipment that is owned or controlled by Amgen at the facilities listed in note (a). Data on the use of natural gas, propane, and diesel in boilers, furnaces, and HVAC are recorded from utility bills or purchase records. Data on the use of diesel in emergency generators are recorded from purchase records or meter readings and, in some cases, estimated from run-hours. Utility bills recorded in units of volume are converted to energy by using the Global Reporting Initiative Version 3.0, EN3 table, to convert volumes of primary sources (natural gas, diesel), or from specific fuel analysis data (diesel used in Juncos, Puerto Rico), and the US Energy Information Administration/Annual Energy Review Table A1 (propane). Energy from emergency generators recorded as run-hours is estimated using the manufacturer's specified fuel-feed rate for each generator.
- (e) Indirect energy use results from purchased energy in the forms of electricity and steam at the Amgen facilities listed in note (a). Data on the use of electricity and steam are recorded from utility bills. Utility bills for purchased steam that are recorded in units of mass (i.e., 'lb steam') are converted to energy by using the latent heat of evaporation from the saturated steam tables, then dividing by the efficiency of the supplier's steam generator.

Carbon

- (f) Scope 1 carbon emissions result from direct energy sources defined in note (c). Carbon emissions from our US sales fleet and executive air fleet are found in the Other Carbon category in this data summary. Carbon data from natural gas sources are calculated using regional specific emission factors from US EPA Rule Part 98A Table C-3 (US weighted average) for all US sites; from the Ireland UFCCC for Amgen's facility in Dun Laoghaire, Ireland; from U.K. Defra/DECC's 110819 Guidelines for Amgen's facilities in the United Kingdom (Uxbridge, Abingdon, and Cambridge); from the NL Agency standard CO₂ emission factors for Amgen's facility in the Netherlands (Breda); and from the Methodology for Reporting 2011 Version 2.0/Ministry of Environment Victoria, BC, December 2011, for Amgen's facility in Burnaby, Canada. Carbon emissions data from propane and diesel fuel sources (except Amgen's facility in Juncos, Puerto Rico) are calculated using the Greenhouse Gas Protocol Cross-Sector Tools-Stationary Combustion-V.1.0 (Sept 2011). Carbon from diesel use in Amgen's Juncos, Puerto Rico, facility are calculated using specific fuel analysis information and from US EPA Rule Part 98A Table C-1. Carbon data from direct energy sources prior to 2011 were calculated using emission factors from the Greenhouse Gas Protocol Cross-Sector Tools-Stationary Combustion-V.1.0 (Jul 2009). Scope 1 emissions that are not included in this data summary include fugitive emissions from chillers, coolers, and HVAC, as well as process-related emissions from cell respiration (carbon as a by-product) and pH adjustments (CO₂ injection). Analysis of these sources in 2012 showed that our fugitive emissions are less than 3 percent of total carbon emissions when compared with other sources such as energy use and that cell respiration and emissions from pH adjustments are negligible (less than 0.1 percent of our total carbon emissions). Processes are in place to maintain chillers, coolers, and HVAC equipment to prevent unintended emissions. Amgen has not included fugitive emission sources as a core emission but will continue to monitor these impacts.
- (g) Scope 2 carbon emissions result from indirect energy sources defined in note (d). Carbon data from purchased electricity are calculated using emission factors from US EPA eGRID2010 10/11/2011 Version 3.2 (2007 data: eGRID subregion annual carbon output emission rate) for all US locations except Amgen's facility in Puerto Rico which has been determined using EPA GHG Report YE 2011 for Power Suppliers in Puerto Rico; from the Greenhouse Gas Division, Environment Canada (2006 data)-V.1.0 (April 2009) for Amgen's facility in Burnaby, Canada; and from specific utility annual providers' reports for Amgen facilities in the United Kingdom (Uxbridge, Abingdon, and Cambridge), the Netherlands (Breda), and Dun Laoghaire, Ireland. Carbon data from purchased steam are calculated using the Emission Factor for Natural Gas as identified in US EPA Rule Part 98A Table C-3 (US weighted average) for Amgen's facility in Cambridge, Massachusetts. Carbon data from indirect energy sources prior to 2011 were calculated using emission factors from US EPA eGRID2007 Version 1.1 for US facilities.

Other Carbon

- (h) The Other Carbon category contains Scope 1 and Scope 3 carbon emissions that are tracked but not included in our current CO₂ reduction target. Carbon emissions from our executive air fleet are calculated using emission factors from the Greenhouse Gas Protocol Cross-Sector Tools-Transport-Fuel-Use (Sept 2011). Carbon emissions from our US sales fleet are calculated using emission factors from the GHG Protocol Emission Factors for Petrol passenger cars (volume) (GHG Protocol) = 8.81 kg/gal. Fuel use and mileage data are collected at the pump for each vehicle. Carbon emissions from our commercial business travel are calculated by Amgen's travel provider using the Defra tool. Carbon emissions from Amgen's material transportation have been provided by the carrier using its own specific methods.
- (i) Scope 3 carbon emissions are a consequence of the activities of the Company but occur from sources not owned or controlled by the Company. Scope 3 carbon emissions that are currently tracked include emissions from Amgen's commercial business travel (air and rail) and material transportation.
- (j) Commercial business travel was not tracked in 2007 or 2008. Material transportation was not tracked from 2007 to 2011.

Water

- (k) Slight discrepancy between values for total water fate and total water withdrawal is due to rounding and compilation of individual facility totals.

Waste

- (l) Recycling rate is the proportion of waste that is recycled and reused compared with the total volume of routine, nonhazardous waste generated with potential for landfill disposal.
- (m) Treatment means the physical, thermal, chemical, or biological processes that change the characteristics of the waste in order to reduce its volume or hazardous nature, facilitate its handling, or enhance recovery.
- (n) Nonroutine waste constitutes waste generated outside the normal operations of our facilities and consists mainly of construction and demolition waste.

Fleet

- (o) Measurement equivalents: 23.0 MPG-US = 27.6 MPG-Imperial = 10.2 L/100KM = 9.78 KM/L

Business Profile

(p) Corporate political contributions represent Amgen Inc.'s US aggregate contributions among those states where these are permissible. Corporate political contributions to certain candidates for state and local elected offices are permissible in accordance with applicable laws and Amgen policy. Outside the US, the rules governing corporate contributions to political parties and/or organizations vary by country. Amgen complies with all applicable laws and regulations in countries in which it has or intends to have a corporate presence or does business. Amgen adheres to a corporate policy that requires internal legal review before any contribution is made. Amgen considers making such contributions, where they are legally permissible, if the funds will be used to support education and engagement on science, technology, and innovation issues. Additional information may be found in the Corporate Governance section at www.amgen.com.

Amgen Inc.**Reconciliation of GAAP Net Income to “Adjusted” Net Income (Unaudited) (\$ in billions)**

“Adjusted” net income and “adjusted” R&D investment are non-GAAP financial measures. Please see below for reconciliations to US Generally Accepted Accounting Principles (GAAP).

Results for the years ended December 31,	2008	2009	2010	2011	2012
GAAP net income	\$4.052	\$4.605	\$4.627	\$3.683	\$4.345
Adjustments to GAAP net income:					
Restructuring and cost savings initiatives	0.148	0.070	0.118	0.162	0.347
Non-cash amortization of product technology rights acquired in a prior year business combination	0.294	0.294	0.294	0.294	0.294
Acquisition-related expenses	0.001	-	-	0.027	0.176
Non-cash interest expense associated with our convertible notes	0.235	0.250	0.266	0.143	0.140
Expenses/(benefit) related to various legal proceedings	0.288	0.033	(0.001)	0.786	0.064
Stock option expense	0.103	0.115	0.124	0.085	0.059
Amortization of acquired intangible assets, research and development (R&D) technology rights	0.070	0.070	0.070	0.021	-
Write-off of inventory resulting from a strategic decision to change manufacturing processes	0.084	-	-	-	-
	1.223	0.832	0.871	1.518	1.080
Tax effect of the above adjustments (a)	(0.390)	(0.293)	(0.318)	(0.331)	(0.329)
Tax net expense (benefit) related to certain prior period items	-	(0.105)	(0.156)	(0.012)	0.023
California tax law change	-	(0.025)	-	-	-
“Adjusted” net income	\$4.885	\$5.014	\$5.024	\$4.858	\$5.119

Reconciliation of GAAP R&D Expense to “Adjusted” R&D (Unaudited) (\$ in billions)

Results for the years ended December 31,	2008	2009	2010	2011	2012
GAAP R&D expense	\$3.030	\$2.864	\$2.894	\$3.167	\$3.380
Adjustments to GAAP R&D expense:					
Acquisition-related expenses	(0.001)	-	-	(0.007)	(0.050)
Stock option expense	(0.046)	(0.049)	(0.051)	(0.035)	(0.022)
Restructuring and cost savings initiatives	(0.003)	(0.006)	-	0.012	(0.012)
Amortization of acquired intangible assets, R&D technology rights	(0.070)	(0.070)	(0.070)	(0.021)	-
“Adjusted” R&D expense	\$2.910	\$2.739	\$2.773	\$3.116	\$3.296

Notes

(a) The tax effect of the adjustments between our GAAP and “Adjusted” results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). Generally, this results in a tax impact at the US marginal tax rate for certain adjustments, including amortization of intangible assets and non-cash interest expense associated with our convertible notes, whereas the tax impact of other adjustments, including the charge for certain legal proceedings and stock option expense, depends on whether the amounts are deductible in the tax jurisdictions where the expenses are incurred or the asset is located and the applicable tax rate(s) in those jurisdictions.

Health and Safety

(r)	Absentee rate is based on US staff members, including full-time, part-time, management, and nonmanagement. Hours recorded for family medical leave are divided by hours staff members were expected to work to calculate the absenteeism rate (percent).
(s)	Injury and illness rate is calculated based on the number of reported Amgen staff member injuries and illnesses beyond first aid. The rate is based on the number of injuries and illnesses per 100 Amgen staff members. Data as of March 2013.
(t)	Lost day case rate is the number of injury and illness cases involving days away from work per 100 Amgen staff members. Data as of March 2013.
(u)	Severity rate is the actual number of days away from work due to injury or illness per 100 Amgen staff members. Data as of March 2013.
(v)	In 2009, we expanded our data tracking to include all contractors that work at our facilities. Previously the 2007 and 2008 data only included contractors working on large capital construction projects.

Compliance

(w)	Notices of violation (NOVs) reported that resulted from agency inspections.
-----	---



INDEPENDENT VERIFICATION STATEMENT

Introduction and objectives of work

Bureau Veritas North America, Inc. (Bureau Veritas) has been engaged by Amgen to conduct an independent assurance of selected environmental data included in Amgen's 2012 Environmental Sustainability Report.

This Assurance Statement applies to the related information included within the scope of work described below.

The data presented in Amgen's 2012 Environmental Sustainability Report is the sole responsibility of the management of Amgen. Bureau Veritas was not involved in the drafting of the Report. Our sole responsibility was to provide independent verification of the accuracy of selected information included in the Report.

Scope of work

Amgen requested Bureau Veritas to verify the accuracy of the following environmental health and safety data summarized in Amgen's Environmental Sustainability Report for the Calendar Year 2012 reporting period:

- Energy Use (Total, Direct and Indirect)
- Greenhouse Gas Emissions (Direct Scope 1 and Indirect Scope 2)
- Water Withdrawal and Fate
- Waste Quantities and Disposition
- Fleet Fuel Efficiency
- Safety Metrics including Injury and Illness Rate, Lost Day Rate and Severity Rate
- Number of Environmental Violations

Excluded from the scope of our work is any verification of information relating to:

- Text or other written statements associated with Amgen's 2012 Environmental Sustainability Report
- Activities outside the defined verification period of Calendar Year 2012

Methodology

As part of its independent verification, Bureau Veritas undertook the following activities:

1. Interviews with relevant personnel of Amgen regarding data collection and reporting systems;
2. Review of Amgen's data and information systems and methodology for collection, aggregation, analysis and internal audit of information used to determine the environmental data;
3. Review of documentary evidence produced by Amgen;
4. Audit of Amgen's data traced back to the source during visits to two manufacturing facilities: one in Juncos, Puerto Rico; and, one in West Greenwich, Rhode Island; and
5. Visit to Amgen's headquarters location in Thousand Oaks, California to review consolidation of site data and to review data collected at a central location.



Amgen

Page 2

Our work is conducted against BVNA's standard internal procedures and guidelines for external verification/assurance of sustainability reports, based on current practice in independent assurance. In accordance with our internal procedures for limited assurance, we use the International Standard on Assurance Engagements (ISAE) 3000 and ISO Standard 14064-3 Greenhouse gases - Part 3: Specification with Guidance for the Validation and Verification of Greenhouse Gas Assertions as reference standards. For this assignment, we are also using the GRI Reporting Framework as a reference standard.

The work was planned and carried out to provide limited verification and we believe it provides an appropriate basis for our conclusions.

Our findings

On the basis of our methodology and the activities described above:

- Nothing has come to our attention to indicate that the reviewed information within the scope of our verification is not materially correct.
- Nothing has come to our attention to indicate that the reviewed information is not a fair representation of the actual environmental and health and safety data for calendar year 2012.
- It is our opinion that Amgen has established appropriate systems for the collection, aggregation and analysis of quantitative data, including energy use, direct and indirect GHG emissions, water withdrawal and fate, waste quantities and disposition, fleet fuel efficiency, injury and illness rate, lost day rate and severity, and number of environmental violations.

Statement of independence, impartiality and competence

Bureau Veritas is an independent professional services company that specializes in Quality, Health, Safety, Social and Environmental management with almost 180 years of history in providing independent assurance services, and an annual 2012 revenue of 3.9 Billion Euros.

No member of the verification team has a business relationship with Amgen, its Directors or Managers beyond that required of this assignment. We have conducted this verification independently, and there has been no conflict of interest.

Bureau Veritas has implemented a Code of Ethics across the business to maintain high ethical standards among staff in their day to day business activities.

Attestation:

Lisa S. Barnes, Lead Verifier
 Technical Director, Climate Change Services
 Bureau Veritas North America, Inc.
 Denver, Colorado


David C. Reilly, Project Reviewer
 Senior Project Manager
 Bureau Veritas North America, Inc.
 Costa Mesa, California

April 8, 2013



“Our sustainability achievements exemplify how science and innovation applied across Amgen support our aspiration to dramatically improve patients’ lives.”

— Robert A. Bradway, Chairman and CEO, Amgen



sam  **2012
sector mover**

To view Amgen's full 2012 Environmental Sustainability Report, see environment.amgen.com. We welcome your feedback at esfeedback@amgen.com.

AMGEN[®]

Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
www.amgen.com